Mekon

Mekonos is a San Francisco-based biotechnology company developing a proprietary platform for high-throughput, ex vivo cell engineering. The company's "Iris" technology utilizes a silicon chip integrated with thousands of individually addressable nanoneedles to deliver molecular payloads—such as CRISPR-Cas9, mRNA, and DNA—directly into cells with high precision. By bypassing the need for viral vectors or harsh electroporation, Mekonos aims to improve cell viability and reduce the complexity of manufacturing cell and gene therapies. The platform is designed to be indication-agnostic, with primary applications in oncology, immunology, and regenerative medicine. Mekonos has established collaborations with major pharmaceutical companies, including Novartis, to advance the next generation of personalized medicines.